Peficitinib 50,100 and 150 mg each showed statistically significantly higher ACR20 response rates compared with placebo,and response rates increased up to 150 mg with a statistically significant dose-response is known[4].Decernotinib (VX-509), an oral selective inhibitor of JAK-3, was also tested in patients with rheumatoidarthritis (RA) in whom the response to methotrexate treatment was inadequate. Here, JAK3 is linked to rheumatoid arthritis.